News Release

Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: In this systematic review and meta-analysis that included 41 randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types, but is not suitable for others. These results have implications for clinical trials of multicancer screening tests. 

Authors: Hilary A. Robbins, Ph.D., M.H.S., M.S.P.H., of the International Agency for Research on Cancer in Lyon, France, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2024.5814)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the American Association for Cancer Research Annual Meeting 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.5814?guestAccessKey=c6b0b8b9-a1d0-436b-bab5-dfd9275c5161&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040724


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.